1. for use with most standard and prefilled syringes
Electronic Injector
for use with most standard and prefilled syringes

2. THE PROBLEM: No one likes injections or needles
7-22 % of the public is needle phobic
For these patients, the prospect of injecting causes:
a sick feeling and physical autonomic reactions,
resulting in missed injections,
resulting in poor treatment of underlying medical problems,
resulting in lowered quality of life and medical complications.
Self-injection requires skill, fortitude, and involves an amount of risk*
*(improper positioning can cause bruising, tissue damage, incorrect dosage, and bent needles

3. THE SOLUTION: InnoJect Electronic Injector
our technology makes it easy to perform self-injection
simplifies and improves the injection process experience
VISUAL:
Hides the needle and syringe inside the injector applicator
PHYSICAL:
Provides tonal biofeedback for appropriate steadiness of orientation on skin surface
Contains patent pending pain suppression technology
AUDIO:
Spoken instructions guide the user thru each step of injection (most languages are available)
USABILITY:
Gentle needle insertion, dispensing of medication, and needle retraction via electronic motion control
Reminder timer for next injection (ringtone)

4. THESE: Standard Syringes and Prefilled-Syringes Go In here
Patent Pending

5. Current Products on the Market & Weakness
Insulin Pens (mechanical, manual needle insertion)
Autoinjectors (spring fired, preloaded, single use, expensive)
Autoinjectors (spring fired, loads limited range of syringes)
Jet Injectors (not painless, limited to drugs approved for jet)
Not Competitors
Innoject is a New Market:
Home administered drugs which have one of the following:
no injection aid
requires a larger needle than other injection devices can accommodate
available injection aid is painful and scary to use
These administered drugs totaled 13.7 million prescriptions in U.S. in 2007 (see next slide).

6. INNOJECT: MARKET ANALYSIS & TRENDS IN US
TOTAL ACCESSIBLE MARKET: million projected customers
56 million self-injectable prescriptions in the U.S. annual§
35 million self-injectable prescriptions applicable to InnoJect usage*
17.5 million potential customers per annum**
INITIAL TARGET MARKET: 68,000 projected customers per annum
13.7 million prescriptions are prime candidates for this market space***
6.8 million projected customers available for capture**
1% capture rate = 68,000 InnoJects sold per annum U.S.
§ 2007 NAMCS Data (National Ambulatory Medical Care Survey) and Insurance Survey for Drugs for Home Use by Blue Cross and Blue Shields 2007.
*A percentage of the prescriptions for each drug applicable to our device, according to its specifics, is weighted and used to give a potential market.
**Assumes that half the prescriptions are refills.
***Initial projected market share is based upon the number of pharmaceutical drugs most likely prescribed along with the InnoJect device, is weighted and number calculated.

7. Future Target Markets
Medical facilities where NextGEN InnoJect model is utilized with multiple patients (1 device to multiple patients)
International (underdeveloped countries) pharmaceutical drugs administered in treatment centers
Immunizations stations
Prefilled syringes NOT currently compatible with initial InnoJect model*
* 2.5 billion prefilled syringes used worldwide in 2011.

8. Market Entry Scenario
Contracts with the industry principle(s) for marketing function may be:
distributors
syringe manufacturers
drug manufacturers who wants to distinguish themselves by solving the “self-injection” problem for their product.
Market Entrance Scenario
Self-Injectable drugs are prescribed by a physician.
The physician sees our client, the patient.
InnoJect (Class II medical device) requires prescription.
The InnoJect turns a standard syringe or prefilled syringe into an “autoinjector” with finesse, effectively making the prospect of “self injection” an easy and much less scary task.
Doctor solves patient’s self-injection problem by prescribing the InnoJect to the client along with prescribed self-injectable drug.
Client’s costs covered by insurance company (part of marketing plan).

9. Model Production Timeline
1st Model -(Year 1): BASIC unit (home use*)
(Entry point into market. Basis of Medicare Version.)
2nd Model - (Year 2): BASIC unit Plus*
(New feature added: pain suppression technology )
3rd Model - (Year 4): Multiple patient unit with twist-off needle shield. (Disposable sterile needle shields allow for repeat use on multiple patients. Provides repeat sales of disposable needle shields.)
*Basic unit - home use/plus pain suppression models: patient purchases 1 unit that is reusable for multiple injections... not multiple patients.

10. Facts about the Fear of Needles
Approximately 20 percent of the general population has some degree of fear associated with needles and injections.
As much as 10 percent of people suffer from a phobia called trypanophobia, which is a fear of needles and injections.
Traumatic experiences in childhood form the foundation of these fears—like seeing an older sibling cry when getting their shots.
Of those who have a fear of needles, at least 20 percent avoid medical treatment as a result.
The fear of needles is both a learned and an inherited condition. A fairly small number inherit a fear of needles, but most people acquire needle phobia around age four to six.
reference: Healthline.com

11.
Copyright© September 2015